Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to start review
Explore by Goal
"The biology of mind bridges the sciences – concerned with the natural world – and the humanities – concerned with the meaning of human experience."
- Eric Kandel
Quick Answer
Copied
Core claim
CDC14A/B phosphatases are proposed to regulate adipogenesis and metabolic phenotypes by directly dephosphorylating PPARγ (notably S112, S273, T296), thereby shifting PPARγ activity toward differentiation; in vivo, Cdc14 double-KO mice show resistance to HFD-induced obesity/steatosis/glucose intolerance, and in vitro differentiation defects can be rescued by the PPARγ agonist troglitazone.
Long Answer
BGPT Visual Paper Review (skeptical, evidence-anchored)
Test whether CDC14A/B phosphatases control adipogenesis and glucose metabolism by directly antagonizing phosphorylation of the PPARγ master regulator, with biochemical pinpointing of residues S112, S273, and T296 and rescue by troglitazone.
Figure A — In vivo HFD phenotype signals (reported relative magnitudes)
Only values explicitly stated in the provided text are plotted (no imputation).
Evidence anchors
Under 45% HFD for 6 weeks, Cdc14 DKO mice show near-static body weight with ~10% gain vs ~30% gain in controls.
WAT accumulation is reported as ~4× lower in DKO vs WT (plotted as 0.25 relative mass).
Adipocyte area is reported as ~3× smaller in DKO vs WT at experiment end (plotted as 1/3 relative area).
Figure B — In vitro adipogenesis directionality by CDC14 isoform
Only “~70% reduction” and “~45% enhancement” are plotted, as stated in text.
CDC14B depletion in ESCs is stated to cause a drastic reduction in differentiation of almost 70% (plotted as ~0.30 relative).
CDC14A depletion is stated to significantly enhance adipogenic differentiation by approximately 45% (plotted as ~1.45).
Figure C — Proposed mechanistic chain (as stated in the paper)
This is a mechanistic “wiring diagram” of evidence the authors claim, not a proof of sufficiency.
Direct biochemical support for the PPARγ residue claims
The paper states CDC14B can dephosphorylate PPARγ after ERK2/CDK5 phosphorylation and reports residue-specific dephosphorylation outcomes including S112, S273, and T296 (and explicitly notes T75 is unaffected in the stated assays).
Troglitazone is reported to rescue adipogenic differentiation in CDC14 DKO cells, supporting PPARγ activity as a key mediator (within the experimental system used).
Figure D — Claim-to-evidence map (skeptical grading)
Grading reflects internal methodological triangulation described in the provided text (not a formal peer-review score).
HFD feeding; body weight; WAT mass; liver steatosis; ITT/GTT; metabolic monitoring
Multiple orthogonal phenotypes + monitoring suggesting changes aren’t simply due to energy expenditure differences (as reported)
Sample sizes per panel are not fully uniform in text; metabolic readouts may still be influenced by unmeasured factors (e.g., subtle feeding behavior details beyond reported intake/rearing changes)
CDC14B promotes adipogenic differentiation in ESCs
CRISPR depletion; Oil Red O at day 24; mRNA changes
Co-IP; in vitro kinase/phosphatase; residue-specific phospho readouts; phosphoproteomics/PRM
Residue-specificity claims connect biochemical dephosphorylation to residue identity and kinase origin (ERK2 vs CDK5)
Direct causal link from each residue to the full metabolic phenotype is explicitly acknowledged as unresolved (“exact contribution… remains unknown”)
Troglitazone rescues adipogenesis in CDC14 DKO cells via PPARγ activity
Pharmacological rescue in differentiated system
Pharmacological functional rescue supports a mediator relationship
Troglitazone can have pleiotropic effects; rescue doesn’t prove the residue-level mechanism is correct in vivo
Figure E — Skeptical critique & falsification pressure points
1) Mechanism residue causality is not fully resolved
The paper demonstrates CDC14B dephosphorylates multiple PPARγ residues, but explicitly states the exact contribution of each residue to the final phenotype remains unknown.
2) In vivo vs in vitro discordance & compensation
The authors report isoform compensation: Cdc14a loss upregulates Cdc14b transcripts and vice versa, and single isoform phenotypes show divergence between in vivo and in vitro systems (e.g., CDC14B affects adipogenesis in vitro but not strongly in vivo in their single-KO HFD experiments).
3) Pharmacological rescue doesn’t uniquely validate the phosphatase mechanism
Troglitazone rescue supports that PPARγ activity is downstream of the deficiency, but it remains possible that CDC14 also affects adipogenesis through additional pathways; the rescue is consistent with the model but not uniquely diagnostic.
4) Systems-level confounds
The paper includes metabolic monitoring (VO2/VCO2/EE/RQ) and notes no significant differences, but it also reports increased rearing activity and water intake in DKO during one period; even subtle behavior changes can affect whole-body phenotypes.
Figure F — Why this mechanism is plausible within CDC14 biology
CDC14 is known as a CDK-counteracting phosphatase family with diverse (and sometimes redundant) roles
Reviews and earlier work highlight that vertebrate CDC14 paralogs have context-dependent functions beyond yeast mitotic exit, with redundancy and species-specific divergence complicating substrate mapping.
Yeast work shows CDC14 can reverse CDK phosphorylation to trigger mitotic exit network transitions, reinforcing biochemical plausibility of “kinase phosphorylation → CDC14 reversal” logic.
BGPT “What would change my mind?”
If residue-specific PPARγ mutants (e.g., phosphomimetic vs nonphosphorylatable at S112/S273/T296) fail to reproduce the adipogenesis and metabolic directionality observed in CDC14 loss, then the residue-level causal model weakens. (This follows directly from the paper’s own statement that residue contributions are not fully resolved.)
If troglitazone rescue works but PPARγ activity readouts do not align with the proposed phosphorylation state changes (S112/S273/T296) across genotypes, then troglitazone may bypass the phosphatase mechanism.
If in vivo metabolic protection is preserved in contexts where PPARγ phosphorylation regulation is chemically/biochemically uncoupled from CDC14 action, the model’s central mediation through PPARγ becomes less necessary. (The paper currently provides the mediation link primarily through rescue in vitro.)
Targeted BGPT next questions
Author reviews (BGPT)
Feedback:
Updated: April 27, 2026
BGPT Paper Review
Study Novelty
90%
The paper proposes a relatively direct phosphatase→nuclear receptor phosphorylation mechanism in adipogenesis: CDC14B is claimed to dephosphorylate multiple specific PPARγ residues (S112, S273, T296) and the adipogenesis phenotype is interpreted via PPARγ activity with troglitazone rescue—an unusually mechanistically tight link among CDC14 biology, PPARγ PTM regulation, and differentiation/metabolic phenotypes.
Scientific Quality
80%
Scientific quality is supported by multi-level triangulation in the provided text (in vivo HFD phenotyping + in vitro genetic perturbation + residue-targeted biochemical assays + phosphoproteomics + pharmacological rescue) and by explicit acknowledgement of uncertainty in residue contributions. Skeptical concerns remain around isoform compensation, residue-by-residue causal dissection, and the limits of pharmacological rescue as a uniquely diagnostic test of the phosphatase→PTM chain.
Study Generality
70%
The study adds to a broader principle—CDK-counteracting phosphatases coordinating proliferation/differentiation—yet its direct substrate claim is tightly anchored to mammalian CDC14A/B and PPARγ PTM regulation in adipogenesis. Generality to other cell types and to humans remains to be established within the provided text.
Study Usefulness
90%
Practical value is high for mechanistic hypothesis-building: it offers a testable CDC14B→PPARγ phosphorylation-state model with concrete residues and assay modalities (residue-specific phospho readouts, PRM/phosphoproteomics) that can be used to design causality tests and follow-up experiments.
Study Reproducibility
80%
The provided text includes substantial method detail (mouse diet composition/feeding duration, differentiation protocol outline, Oil Red O quantification approach, CRISPR strategy, kinase/phosphatase assay outline, LC-MS/MS acquisition modes and PRM analysis details, and data deposition identifiers). Remaining reproducibility uncertainty exists because full statistical n’s per panel are not uniformly extractable from the provided text blob and because some figures are referenced without raw underlying numeric tables.
Explanatory Depth
90%
The paper moves beyond phenotypic association by proposing a direct biochemical substrate mechanism (CDC14B dephosphorylating PPARγ residues) and connecting it to a functional rescue outcome (troglitazone in DKO cells). It still leaves residue-level contribution mapping incomplete, but the mechanistic depth is high relative to typical adipogenesis studies.
It will download RNA-seq (GSE292631) and proteomics/phospho (PXD062111), then compute residue- and pathway-level enrichment differences across CDC14 genotypes over the adipogenic time course, producing ranked target lists and correlation plots.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A “single-residue-only” model is weakened because the paper reports CDC14B dephosphorylates multiple PPARγ residues (S112, S273, T296) and acknowledges that the exact contribution of each residue to the final phenotype remains unknown.
A “troglitazone rescues but does not involve phosphorylation state” model is less preferred because the authors’ mechanistic core explicitly links CDC14B catalytic dephosphorylation at specific residues to PPARγ activity and then uses troglitazone as a functional convergence point. However, this alternative remains testable because rescue does not uniquely validate the phosphatase mechanism.
Quick Answer
Long Answer
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
